Domain | Measurement | Total (n = 100) | Dementia (n = 73) | MCI (n = 27) | n available |
---|---|---|---|---|---|
Demographics | Sex, n female (%) | 10 (10%) | 8 (11%) | 2 (7%) | 100 |
Age, years | 69 ± 6 | 70 ± 5 | 67 ± 7 | 100 | |
Disease duration, years | 4 ± 3 | 4 ± 3 | 4 ± 2 | 99 | |
Education, years | 12 ± 3 | 12 ± 3 | 12 ± 3 | 100 | |
MMSE | 25 ± 3 | 24 ± 3 | 27 ± 2 | 100 | |
APOE-e4 carrier | 39 (47%) | 26 (47%) | 10 (46%) | 77 | |
Core clinical features | Parkinsonism | 69 (69%) | 54 (75%) | 15 (56%) | 99 |
Visual hallucinations | 39 (39%) | 32 (44%) | 7 (27%) | 99 | |
Cognitive fluctuations | 45 (46%) | 38 (53%) | 7 (27%)* | 98 | |
RBD | 75 (77%) | 55 (76%) | 20 (77%) | 98 | |
Suggestive neuropsychiatric symptoms | Depressive symptoms | 18 (19%) | 14 (20%) | 4 (16%) | 95 |
Delusions | 7 (7%) | 7 (10%) | 0 | 99 | |
Anxiety | 40 (44%) | 31 (44%) | 9 (41%) | 92 | |
Apathy | 56 (61%) | 45 (64%) | 11 (50%) | 92 | |
Suggestive autonomic symptoms | Orthostatic hypotension | 63 (64%) | 46 (63%) | 17 (65%) | 99 |
Constipation | 34 (34%) | 29 (40%) | 5 (19%)* | 100 | |
Urinary problems | 47 (47%) | 33 (45%) | 14 (52%) | 100 | |
Hynosmia | 52 (54%) | 40 (56%) | 12 (46%) | 97 | |
Assessment of disease burden | Functional Activities Questionnaire | 12 ± 6 | 13 ± 6 | 8 ± 6* | 98 |
Quality of Life-AD | 31 ± 5 | 31 ± 5 | 31 ± 5 | 100 | |
Zarit caregiver burden interview | 25 ± 15 | 26 ± 14 | 19 ± 16 | 77 | |
Imaging | 123FP-CIT-SPECT, n abnormal (%) | 70 (88%) | 47 (87%) | 22 (88%) | 80 |
Medial temporal atrophy | 1 [0.5–1.5] | 1 [0.5–1.5] | 0.5 [0–1]* | 95 | |
Posterior cortical atrophy | 1 [1–2] | 1 [1–2] | 1 [0.5–1] | 95 | |
Global cortical atrophy | 1 [0–1] | 1 [0–1] | 0 [0–1]* | 95 | |
Fazekas | 1 [0–1] | 1 [1–1] | 0 [0–1] | 94 | |
Microbleeds, presence, n (%) | 12 (13%) | 8 (12%) | 4 (17%) | 90 | |
EEG/MEG (n = 68/n = 7) | Abnormal EEG/MEG (severity ≥2) | 72 (96%) | 52 (98%) | 20 (91%) | 75 |
Severe abnormal EEG/MEG (severity = 3) | 60 (80%) | 46 (89%) | 14 (64%)* | 75 | |
CSF | Aβ42, n abnormal (%) | 51 (70%) | 39 (74%) | 12 (60%) | 73 |
t-tau, n abnormal (%) | 27 (37%) | 19 (36%) | 8 (40%) | 73 | |
p-tau, n abnormal (%) | 29 (40%) | 20 (38%) | 9 (45%) | 73 | |
p-tau/Aβ42, n abnormal (%) | 39 (53%) | 30 (57%) | 9 (45%) | 73 |